Please use this identifier to cite or link to this item:
Title: Reduced mortality of Staphylococcus aureus bacteremia in a retrospective cohort study of 2139 patients: 2007 - 2015.
Austin Authors: Austin, Eloise D;Sullivan, Sean S;Macesic, Nenad;Mehta, Monica;Miko, Benjamin A;Nematollahi, Saman;Shi, Qiuhu;Lowy, Franklin D;Uhlemann, Anne-Catrin
Affiliation: New York Presbyterian Hospital, New York, New York, USA
Department of Public Health, School of Health Sciences and Practice, New York Medical College, Walhalla, New York, USA
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Department of Medicine, Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York, USA
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Department of Pathology and Cell Biology, Clinical Microbiology Laboratory, Columbia University Medical Center, New York, New York, USA
Department of Medicine Microbiome & Pathogen Genomics Core, Columbia University Medical Center, New York, New York, USA
Issue Date: Apr-2020 2019-06-11
Publication information: Clinical Infectious Diseases 2020; 70(8): 1666-1674
Abstract: Understanding the changing epidemiology of Staphylococcus aureus bacteremia, as well as the clinical variables associated with poor outcomes, can yield insight into potential interventions. This study was a retrospective, observational cohort study of adult patients at an academic medical center in New York City who had S. aureus bloodstream infection between January 1, 2007 and December 31, 2015. Participants were divided into three periods: Group 1 (2007-09), Group 2 (2010-12), and Group 3 (2013-15) for analysis of trends. All clinical strains were genotyped (spa.) The main outcome was 30-day all-cause mortality. There were 1264 episodes of MSSA and 875 episodes of MRSA bacteremia, with a rising proportion due to MSSA (55% G1;. 59% G2; 63% G3, p = 0.03.) There were no significant changes in variables such as average age, gender, Charlson score, proportion of hospital-onset (HO) infections, and distribution of dominant strain genotypes. Mortality in MRSA infection was unchanged (25% G1; 25% G2; 26% G3), while mortality in MSSA infection significantly declined (18% G1; 18% G2; 13% G3.) From 2007-2015, there was a decrease in the average time to anti-staphylococcal therapy (AST) in MSSA infection (3.7 days G1; 3.5 G2; 2.2 G3.) In multivariate analysis, AST within 7 days of initial positive MSSA culture was associated with survival. Mortality in MSSA bloodstream infection is declining, associated with a decrease in time to targeted therapy. These results emphasize the potential for rapid diagnostics and early optimization of treatment to impact outcomes in MSSA bacteremia.
DOI: 10.1093/cid/ciz498
Journal: Clinical Infectious Diseases
PubMed URL: 31185081
Type: Journal Article
Subjects: Staphylococcus aureus
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.